Regulatory Changes and Their Impact on Peptide Use in Sports

Two rulebooks, one unusual year

As of October 2026, US drug rules for peptides have shifted more in the past year than in the three years before it. Their status in sport hasn't shifted at all. The two are easy to blur, so it helps to keep them apart: FDA decides who may legally make and sell a peptide in the US, and WADA's Prohibited List decides whether a tested athlete may use it. A change on one track says nothing about the other.

An earlier version of this page said BPC-157, TB-500, CJC-1295, ipamorelin and thymosin alpha-1 sat on FDA's Category 2 "do not compound" list. That was broadly true in 2023 and is wrong now. Below is the timeline, followed by what it means for tested athletes and for lifters who are never tested.

How the compounding route closed

US compounding pharmacies working under Section 503A of the Food, Drug, and Cosmetic Act can't make a drug from just any raw ingredient. The bulk substance has to meet a USP or NF monograph, be a component of an FDA-approved drug, or appear on FDA's 503A bulks list. While FDA reviews nominations for that list, it sorts them into interim categories. Category 1 substances can generally be compounded during the review. Category 2 holds substances FDA says raise significant safety risks, and a pharmacy that compounds them risks enforcement.

Beginning in 2023, FDA placed roughly 19 peptides in Category 2, according to a July 2026 analysis by LumaLex Law. The firm's reading is that this pulled a group of widely used peptides out of the legitimate compounding supply and pushed demand toward gray and black markets. Ipamorelin acetate, for example, went into Category 2 for 503B outsourcing facilities on September 29, 2023, and FDA's safety-risk page still lists it there. FDA also changed the process: its guidance says substances nominated on or after January 7, 2025 won't be placed in any category.

The 2026 reversal, so far

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. publicly signaled that most of the restricted peptides (LumaLex counts roughly 14 of 19) should move back toward legal compounding. FDA's steps since then:

• April 2026. FDA removed 12 peptides from Category 2 because their nominators withdrew the nominations, according to Frier Levitt. BPC-157, MOTS-c, melanotan II and TB-500 (which FDA lists as thymosin beta-4 fragment LKKTETQ) are among them.
• July 23-24, 2026. FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed seven of the 12. By LumaLex's tally, it voted to recommend six for the 503A bulks list, including BPC-157 (8-6-1), TB-500 (8-6-1) and MOTS-c (7-5-2), and voted against DSIP (6-7-1).
• Before the end of February 2027. A second PCAC meeting is planned for GHK-Cu, melanotan II, LL-37, dihexa and PEG-MGF.

Leaving Category 2 isn't permission to compound. These peptides now sit in no category, and a committee vote is advice to FDA, not a rule. Boesen & Snow Law describes three events that the market keeps treating as one: removal from Category 2, a favorable PCAC vote, and actual placement on the bulks list. "Only the third one changes what a pharmacy may lawfully compound," the firm wrote on August 4, 2026, adding that FDA had taken no formal step since the vote. As of early October 2026, no proposed rule had been reported.

Where sport-relevant peptides stand

The compounding column below comes from FDA's May 14, 2026 category list and its safety-risk page. The WADA column comes from the 2026 Prohibited List, which is in force through December 31, 2026.

Tesamorelin is a different case. It's an FDA-approved prescription medicine (Egrifta) for excess abdominal fat in HIV-associated lipodystrophy, so it isn't part of the bulk-ingredient process at all. WADA prohibits it under S2.2.4 regardless.

What it means for tested athletes

Nothing in FDA's 2026 actions changes a peptide's status in sport. WADA's 2026 List puts BPC-157 in S0, which covers any substance not addressed elsewhere on the List "with no current approval by any governmental regulatory health authority for human therapeutic use." USADA notes that BPC-157 wasn't prohibited before 2022, when it was added to S0. Eligibility for compounding isn't approval for therapeutic use, so on our reading BPC-157 would stay in S0 even if FDA added it to the bulks list. TB-500 and the growth hormone secretagogues sit in S2, which doesn't depend on approval status.

The 2027 List, which takes effect on January 1, 2027, widens the net. USADA's summary says "peptides" in general are now named in the S0 class. It also warns that prohibited peptides may be sold under different names or slang terms, and that some experimental peptides sold online may not be on anti-doping organizations' radar yet. Missing from the List by name doesn't mean allowed.

Two more consequences follow from how anti-doping rules work. Athletes are, in USADA's words, "ultimately responsible for what is in their systems," so a research-use-only label offers no defense. Contamination adds a second risk: CBS News reported that Paradigm Peptides, whose owner was sentenced in July 2026, sold products adulterated with steroids. For a tested athlete, a vial like that could mean a positive for an anabolic steroid on top of the peptide itself. Detection methods and the bans that follow a positive test are covered in our guide to the legal implications of peptide use in sports.

The List answers what's prohibited. Whether using an allowed or untested compound is fair, and how much personal risk is acceptable, is a separate question, taken up in our article on the ethics of performance enhancement.

What it means for lifters who aren't tested

For untested lifters, the bigger effect is on supply. The 2026 changes haven't reopened pharmacy access to BPC-157 or TB-500, because neither is on the bulks list yet. Most people using them still buy from research-use-only (RUO) vendors.

FDA has said plainly that the RUO label doesn't protect those sellers. In an August 24, 2026 warning letter to Peak Performance Peptides, the agency wrote that "despite statements on your product labeling marketing your products for 'research use only' and 'not for human consumption,' evidence obtained from your website establishes that your products are intended to be drugs for human use." It also pointed to the seller's bacteriostatic water as providing the means to prepare an injectable drug. The products named in that letter included retatrutide, semaglutide, SS-31, PT-141 and tesamorelin. Criminal cases are rarer. On July 30, 2026, a federal judge sentenced Paradigm Peptides owner Matthew Kawa to 70 months in prison, a penalty CBS News described as rare for a seller of research-labeled peptides.

Users on peptide forums describe favorite vendors going quiet or closing; we haven't verified individual cases. Our piece on why research-chemical suppliers can disappear looks at the warning signs. Other countries are moving the same way. Health Canada's April 9, 2026 advisory listed unauthorized injectable peptides it had seized, including BPC-157, CJC-1295, ipamorelin, TB-500 and MOTS-c, and told consumers not to buy or use them.

With no pharmacist in the chain, the buyer carries the job of checking what's in the vial. Independent HPLC and mass spectrometry testing can confirm a sample's identity and purity, but a certificate of analysis (COA) describes one batch, and it's only useful if it's genuine. Our article on the health risks of unregulated peptides covers contamination and mislabeled vials, and peptide sourcing and legality compares the supply channels and what a COA can and can't show.

What to watch next

• Whether FDA proposes a rule for the six peptides the PCAC backed, or places them in Category 1 on an interim basis while rulemaking proceeds, an option LumaLex describes as possible. Either step would affect US compounding, not status in sport.
• The second PCAC meeting, due before the end of February 2027.
• The 2027 Prohibited List from January 1, 2027, and how anti-doping organizations apply the broader S0 wording on peptides.
• Further FDA warning letters and criminal cases against research-use-only sellers.